Chief Executive Officer, Pathios Therapeutics
| Role | Organisation | Sources |
|---|---|---|
| Chief Executive Officer | Pathios Therapeutics | biomelbourne.org, Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Head of Pharmacology (former) | Vertex | Brandon Capital portfolio |
Stories naming Stuart Hughes. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Cancer immunotherapy biotech Pathios Therapeutics has completed the initial tranche of a Series B round, bringing in Bristol Myers Squibb as a new strategic backer alongside prior backers Canaan and Brandon Capital.
UK cancer biotech Pathios Therapeutics, backed by Canaan Partners and Brandon Capital, presented preclinical data at a US conference showing its GPR65 inhibitor PTT-3213 shrank tumors in mouse models.